Estimating medication persistency using administrative claims data.
暂无分享,去创建一个
Rishi Sikka | R. Aubert | R. Sikka | Fang Xia | Ronald E Aubert | Fang Xia
[1] D. Sclar,et al. Utility of a transdermal delivery system for antihypertensive therapy. Part 2. , 1991, The American journal of medicine.
[2] C. Dezii. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. , 2000, Managed care.
[3] M. Gill,et al. Antiretroviral medication adherence and persistence with respect to adherence tool usage. , 2000, AIDS patient care and STDs.
[4] Hu Js,et al. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. , 1998 .
[5] J. LeLorier,et al. Predictors of persistence of use of the novel antidiabetic agent acarbose. , 2001, Archives of internal medicine.
[6] J. Caro. Stepped care for hypertension: are the assumptions valid? , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[7] J. K. Won,et al. Effect of value–added utilities on prescription refill compliance and Medicaid health care expenditures–a study of patients with non–insulin–dependent diabetes mellitus , 1993, Journal of clinical pharmacy and therapeutics.
[8] M. Weinstein,et al. Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.
[9] G. Schwartz,et al. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. , 2004, American journal of ophthalmology.
[10] M. Tran,et al. Effects of Once-Daily and Twice-Daily Dosing on Adherence With Prescribed Glipizide Oral Therapy for Type 2 Diabetes , 2002, Southern medical journal.
[11] L. Pilote,et al. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[12] C. Mullins,et al. Discontinuation rates of topical glaucoma medications in a managed care population. , 2002, The American journal of managed care.
[13] G. Schwartz,et al. Patient persistency with topical ocular hypotensive therapy in a managed care population. , 2004, American journal of ophthalmology.
[14] Urs A. Meyer,et al. Drug regimen compliance : issues in clinical trials and patient management , 1999 .
[15] B. Martin,et al. Persistence with Estrogen Therapy in a Postmenopausal Medicaid Population , 1999, Pharmacotherapy.
[16] W. Gerth. Compliance and persistence with newer antihypertensive agents , 2002, Current hypertension reports.
[17] D. Sclar,et al. Antidepressant Pharmacotherapy: Economic Evaluation of Fluoxetine, Paroxetine and Sertraline in a Health Maintenance Organization , 1995, The Journal of international medical research.
[18] Hugh Kawabata,et al. Young HIV-infected adults are at greater risk for medication nonadherence. , 2002, MedGenMed : Medscape general medicine.
[19] F. Stracci,et al. Statin compliance in the Umbrian population , 2003, European Journal of Clinical Pharmacology.
[20] S. Benson,et al. Immediate‐Release Oxybutynin versus Tolterodine in Detrusor Overactivity: A Population Analysis , 2000, Pharmacotherapy.
[21] J. Kennedy,et al. Drug affordability and prescription noncompliance in the United States: 1997-2002. , 2004, Clinical therapeutics.
[22] P A Russo,et al. The economic burden of congestive heart failure in a managed care population. , 2000, The American journal of managed care.
[23] G. Dailey,et al. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. , 2001, Clinical therapeutics.
[24] J. LeLorier,et al. Estrogen Replacement Therapy: Determinants of Persistence With Treatment , 2001, Obstetrics and gynecology.
[25] A V Prochazka,et al. The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.
[26] S. Crystal,et al. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS , 2001, Journal of General Internal Medicine.
[27] J. Métry. Measuring Compliance in Clinical Trials and Ambulatory Care , 2002 .
[28] F. Frech,et al. Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting , 2003, Journal of managed care pharmacy : JMCP.
[29] J. Rizzo,et al. Variations in compliance among hypertensive patients by drug class: implications for health care costs. , 1997, Clinical therapeutics.
[30] Y. Moride,et al. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. , 2003, Rheumatology.
[31] G. Dailey,et al. Patient Compliance and Persistence with Anti-Hyperglycemic Therapy: Evaluation of a Population of Type 2 Diabetic Patients , 2002, The Journal of international medical research.
[32] J. Avorn,et al. Persistence of use of lipid-lowering medications: a cross-national study. , 1998, JAMA.
[33] D. Cm. Persistence with drug therapy: a practical approach using administrative claims data. , 2001 .
[34] W. Drevets,et al. Course of antidepressant treatment drug type, and prescriber's specialty. , 1998, Psychiatric services.
[35] A. Perwien,et al. Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity Disorder , 2004, Journal of managed care pharmacy : JMCP.
[36] R. Aubert,et al. Evaluation of a depression health management program to improve outcomes in first or recurrent episode depression. , 2003, The American journal of managed care.
[37] J. K. Won,et al. Utility of a sustained-release formulation for antihypertensive therapy. , 1993, Journal of human hypertension.
[38] L. Pilote,et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. , 2003, American heart journal.
[39] J Urquhart,et al. Some economic consequences of noncompliance , 2001, Current hypertension reports.
[40] J. K. Won,et al. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. , 1993, Journal of human hypertension.
[41] J. LeLorier,et al. Patterns of amlodipine and felodipine use in an elderly Quebec population. , 2000, The Canadian journal of cardiology.
[42] G. Baio,et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. , 2002, Clinical therapeutics.
[43] M. Rich,et al. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. , 1999, American heart journal.
[44] G. Schwartz,et al. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. , 2003, Clinical therapeutics.
[45] A. Capone,et al. Pharmacoeconomics of Antihypertensive Drug Treatment: An Analysis of How Long Patients Remain on Various Antihypertensive Therapies , 2004, Journal of clinical hypertension.
[46] J. Caro,et al. Existing treatment strategies: does noncompliance make a difference? , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[47] W. Gerth,et al. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. , 2001, Clinical therapeutics.
[48] G. Schwartz,et al. Patient Persistency with Pharmacotherapy in the Management of Glaucoma , 2003, European journal of ophthalmology.
[49] J. Hasford,et al. A population-based European cohort study of persistence in newly diagnosed hypertensive patients , 2002, Journal of Human Hypertension.
[50] G. Schwartz,et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. , 2002, The American journal of managed care.
[51] B. Bloom. Continuation of initial antihypertensive medication after 1 year of therapy. , 1998, Clinical therapeutics.
[52] Eric S. Johnson,et al. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. , 2002, The American journal of managed care.
[53] J. P. Wilson,et al. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. , 1997, Clinical therapeutics.
[54] D. Sclar,et al. Effect of health education in promoting prescription refill compliance among patients with hypertension. , 1991, Clinical therapeutics.
[55] J. Kragstrup,et al. High persistence of statin use in a Danish population: compliance study 1993-1998. , 2002, British journal of clinical pharmacology.
[56] S. Crystal,et al. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. , 1995, Health services research.
[57] S. Piñeros,et al. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. , 2003, The American journal of cardiology.
[58] J. Caro,et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[59] R. Düsing,et al. Adverse events, compliance, and changes in therapy , 2001, Current hypertension reports.
[60] J. Caro,et al. Persistence with treatment for hypertension in actual practice. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[61] W. Gerth,et al. Antihypertensive persistence and drug class. , 2002, The Canadian journal of cardiology.
[62] Anke Richter,et al. The impact of reducing dose frequency on health outcomes. , 2003, Clinical therapeutics.